Logo Informatori.Info
feb17

Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone


Pfizer Inc. PFE, +0.33% said early Thursday that its Xeljanz drug met its primary endpoint in combination with methotrexate as compared to AbbVie's ABBV, -0.28% blockbuster drug Humira, although it didn't meet the primary endpoint on its own.


The results of the phase 3B/4 trial, which lasted 12 months and enrolled about 1,150 patients, show Xeljanz's efficacy as a combination therapy for moderate-to-severe rheumatoid arthritis, said Chief Development Officer Michael Corbo. Xeljanz has already been approved for rheumatoid arthritis in the U.S., but pharmaceutical companies have increasingly looked to efficacy data to show the value of their treatments relative to competitors'. Humira is the world's top-selling drug. Pfizer shares have risen 4.9% over the last three months, compared with a 7.9% rise in the S&P 500 SPX, -0.09%

 

17/02/2017 - Categoria: Farmaci - Da: Sh@wn - 772 letture

 

  Commenti

Nessun Commento.

Il tuo Nome
Email
Website
Titolo
Commento
Immagine CAPTCHA
Inserisci il codice

RITORNA ALLA PAGINA PRECEDENTE

Cerca un articolo

Argomenti
Skip Navigation Links.

AIFA

AIISF

Articoli Scientifici

ASL

Associazioni-Sindacati

Auto Aziendale

Aziende Farmaceutiche

British Medical Journal

Codice Strada

Congressi

Contravvenzioni

Dispositivi Medici

Enasarco

Eventi

Eventi ECM

Farmaci

Farmacie

Farmindustria

Faschim

Federaisf

Fonchim

Informatori

Jama

Lancet

New England

Parafarmacie

RSU Aziende

Sanita'

SLF Cobas